Jazz Pharmaceuticals Rating Reiterated by Guggenheim
's stock had its "buy" rating reaffirmed by Guggenheim in a research note issued on Wednesday, AnalystRatings.Net reports.
Wed May 15, 2013
Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest...
Biogen Idec is estimated to post earnings of $2.07 per share in the September quarter.
Tue May 14, 2013
Zosano Pharma, Inc. Appoints as Chief Operations Officer
In this position, Mr. Oza will guide the company's efforts in manufacturing, quality and engineering vital activities to enable the company to accelerate the development of its innovative multi-product portfolio.
Mon May 13, 2013
Jazz Pharmaceuticals Announces Participation In Upcoming Investor Events
An archived version of each audio webcast will be available for at least one week following each respective presentation on the Investors section of the company's website at www.jazzpharmaceuticals.com . Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and ... (more)
Fri May 10, 2013
Jazz Pharmaceuticals Upgraded to Outperform by Zacks
The firm currently has a $61.00 target price on the stock. Shares of Jazz Pharmaceuticals traded up 4.85% during mid-day trading on Friday, hitting $57.96. Jazz Pharmaceuticals has a one year low of $40.38 and a one year high of $60.79. The stock's 50-day moving average is currently $56.45. The company has a market cap of $3.382 billion and a P/E ... (more)
Thu May 09, 2013
The Motley Fool
3 Stocks to Buy on Wednesday's Post-Earnings Weakness
Brian is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.
Tue May 07, 2013
Jazz Pharmaceuticals (JAZZ) Announces Quarterly Results
Jazz Pharmaceuticals released its earnings data on Tuesday. The company reported $1.37 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.35 by $0.02, Analyst Ratings Network.com reports.
Thu May 02, 2013
Jazz Pharmaceuticals risk/reward highly favorable, says Citigroup
Jazz Pharmaceuticals risk/reward highly favorable, says Citigroup Citigroup views the risk/reward on shares of Jazz Pharmaceuticals as highly favorable over the next six months and keeps a Buy rating on the name with a $75 price target.
Wed Apr 24, 2013
Jazz Pharmaceuticals plc to Report First Quarter 2013 Financial Results on May 7, 2013
The announcement will be followed by a conference call and live webcast at A live webcast of the presentation may be accessed from the Investors & Media section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com . Please connect to the website prior to the start of the conference call to ensure adequate time for any software ... (more)